Relationship between Serum Magnesium Level  and Insulin Resistance in Obese Non-diabetic  and Diabetic Patients: Obez ve Obez Olmayan Diabetik Hastalarda İnsulin Direnci ile Serum Magnezyum Düzeyi İlişkisi

Rahma Hamid; Zeynel Abidin Sayiner; Abuzer Çelekli; Mustafa Araz

doi:10.5152/eurjther.2017.136

Authors

Rahma Hamid Department of Biochemistry Science and Technology, Gaziantep University School of Medicine, Gaziantep
Zeynel Abidin Sayiner Department of Endocrinology And Metabolism, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0001-5105-0292
Abuzer Çelekli Department of Biochemistry Science and Technology, Gaziantep University School of Medicine, Gaziantep
Mustafa Araz Department of Endocrinology And Metabolism, Gaziantep University School of Medicine, Gaziantep

DOI:

https://doi.org/10.5152/eurjther.2017.136

Keywords:

Type 2 diabetes mellitus, obesity, insulin resistance, magnesium

Abstract

Objective: Type 2 diabetes mellitus (T2DM) and obesity are multifactorial diseases that include interactions between hereditary and environmental factors. Our study aimed to evaluate the relationship between serum magnesium (Mg) level and insulin resistance (HOMA-IR) in obese non-diabetic subjects and obese patients with T2DM who were compared with healthy controls.

Methods: The present study included 120 subjects of both genders (age, 20-70 years). The subjects were divided into four groups: Group I included 30 healthy subjects as control (8 males and 22 females); group II included 30 obese non-diabetic subjects (6 males and 24 females) with the body mass index (BMI) ≥25 kg/m²; group III included 30 (14 males and 16 females) obese patients with T2DM and disease history <1 year; and group IV included 30 (17 males and 13 females) obese patients with T2DM and disease history >5 years. Endocrinology and metabolism specialists diagnosed T2DM patients. Serum Mg, fasting glucose, fasting insulin, and fasting lipids were measured including the patients’ weight and height. In addition, BMI and HOMA-IR were calculated.

Results: Serum Mg level significantly decreased in group IV (1.72±0.1 mg/dL) compared with group I (2.07±0.1 mg/dL; p<0.05). HOMA-IR significantly increased in group IV (7.9±7.0) compared with group I (1.03±0.3; p<0.05). In addition, serum fasting glucose, serum insulin, and fasting lipids were significantly higher in case groups than in the control group. The serum Mg level was inversely associated with age in all case groups. In group IV, a negative significant correlation was found between serum Mg level and age and HOMA-IR (p<0.01).

Conclusion: A low serum Mg level was found in obese patients with T2DM and obese non-diabetic subjects, whereas a high HOMA-IR level was found in obese patients with T2DM and obese non-diabetic subjects. Obese patients with T2DM show a negative correlation between the serum Mg level with HOMA-IR and age. We recommend measuring the serum Mg level regularly in obese patients with T2DM, especially in elderly patients, and patients who require supplementation.

Metrics

Metrics Loading ...

References

Kahn SE. The relative contributions of insulin resistance and beta cell dysfunction to the pathophysiology of Type 2 diabetes. Diabet. Review 2003; 46: 3-19.

Sarkar A, Dash S, Barik BK, Muttigi MS, Kedage V, Shetty JK, et al. Copper and Ceruloplasmin levels in relation to total thiols and GST in type2 diabetes mellitus patients. Ind j Clin Biochem 2010; 25: 74-6.

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabet research and clinical practice. 2014; 103: 137-49.

Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obesity Reviews 2005; 6: 1-88.

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.

Tracey L, Mclaughlin MD, Gerald M, Reaven MD. Beyond type2 Diabetes: The need for a clinically useful way to identify insulin resistance. The American Journal of Medicine 2003; 114: 501-2.

Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-73.

Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007; 458: 40-7.

Cahill F, Shahidi M, Shea J,Wadden D, GulliverW, Randell E, et al. High dietary magnesium intake is associated with low insulin resistance in the Newfoundland population. Plos ONE 2013; 8: 1-8.

Hedberg J, Haenni A. Increased plasma magnesium concentrations 3 years after biliopancreatic diversion with duodenal switch. Obes Surg 2012; 22: 1708-13.

Guerrero-Romero F, Rodríguez-Morán M. Serum magnesium in the metabolically-obese normal-weight and healthy-obese subjects. Eur J Intern Med 2013; 24: 639-43.

Naheed T, Khan A, Masood G, Yunus BB, Chaudhry MA. Dyslipidemias in type II diabetes mellitus patients in a teaching hospital of Lahore Pakistan. Pak J Med Sci 2003; 19: 283-6.

Rasic-Milutinovic Z, Perunicic-Pekovic G, Pljexa S, Dangic A, Dangic A. Magnesium deficiency in type 2 diabetes. Hippokratia 2004; 8: 179-81.

Augusta CN, Chinyere A, Opara U, Maisie HE, Isonguyo NU. Influence of Age, Gender and Duration of Diabetes on Serum and Urine Levels of Zinc, Magnesium, Selenium and Chromium in Type 2 Diabetics in Calabar, Nigeria. Turkish Journal of Biochemistry-Turk J Biochem 2006; 31: 107-14.

Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type2 diabetes. Cardiovasc Diabetol 2012; 11: 23.

Elementol J, et al. Evaluation of the correlations between magnesium concentration and selected serum lipid components in women and men of different age with chronic kidney failure. 2010; 15: 321-9.

Lima ML, Judith PJ, Barbosa C, Bras TC. Magnesium deficiency and insulin resistance in patients with type2 diabetes mellitus. Endocrinol Metab 2005; 49: 959-63.